Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Conditional Marketing Authorisation for Trastuzumab Deruxtecan

It is intended for the treatment of metastatic HER2-positive breast cancer
15 Dec 2020
Anticancer agents & Biologic therapy;  Breast cancer;  Personalised medicine

On 10 December 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product trastuzumab deruxtecan (Enhertu), intended for the treatment of metastatic HER2-positive breast cancer. Enhertu was reviewed under EMA’s accelerated assessment programme.

The applicant for this medicinal product is Daiichi Sankyo Europe GmbH.

Enhertu will be available as 100 mg powder for concentrate for solution for infusion. The active substance of Enhertu is trastuzumab deruxtecan, a monoclonal antibody-drug conjugate (ATC code: L01XC41) that binds to the human epidermal growth factor receptor 2 (HER2), disrupting HER2 signalling and also mediating antibody-dependent cell-mediated cytotoxicity. In addition, after binding, trastuzumab deruxtecan undergoes internalisation and intracellular cleavage, resulting in release of deruxtecan. Upon release, deruxtecan causes DNA damage and apoptotic cell death.

The benefits with Enhertu are improved objective response rate and duration of response in patients who had received two or more prior anti-HER2 based regimens.

The most common side effects are nausea, fatigue, vomiting, alopecia, constipation, decreased appetite, anaemia, neutropenia, diarrhoea, thrombocytopenia, cough, leucopoenia and headache.

The full indication is:

Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens.

Enhertu should be prescribed by physicians experienced in the use of anticancer medicinal products.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion.

A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is likely to provide comprehensive clinical data at a later stage.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings